The association of MCP-1 level and MCP-1 -2518 A/G and CCR2 190 G/A gene polymorphisms with COPD and pulmonary hypertension; [MCP-1 düzeyi ve MCP-1 -2518 A/G ve CCR2 190 G/A Gen Polimorfizmlerinin KOAH ve Pulmoner Hipertansiyon ile İlişkisi]

ArticleAçık Erişim

Özet

Objective: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease characterized by obstructed airflow in the lungs. Pulmonary hypertension (PH) is a common complication of COPD and it is associated with pulmonary vascular remodelling. Monocyte chemoattractant protein-1 (MCP-1/CCL2) is one of the key chemokines associated with migration of monocytes and macrophages. Both MCP-1 and its receptor CCR2 have been declared to be involved in various diseases. We aimed to research a possible association of MCP-1 level, MCP-1 -2518 A/G and CCR2 190 A/G polymorphisms with COPD and pulmonary hypertension in this study. Material and methods: Eighty patients and eighty controls were included in the study. Serum MCP-1 levels were measured by ELISA method. Restriction fragment length polymorphism (RFLP) procedure was used to detect the genotypes of patients and control group. Results: MCP-1 levels were found to be significantly higher in COPD patients than in healthy controls (P=0.001) and patients with COPD + PH had higher serum MCP-1 levels than COPD patients (P=0.005). No association was found between MCP-1/CCR2 gene polymorphisms and patient groups (COPD and COPD + PH). Conclusion: MCP-1 level seems to be associated with both COPD and pulmonary hypertension. Increased MCP-1 expression may most likely to be involved in the pathogenesis of these diseases. © Copyright 2021 by Gazi University Medical Faculty

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13388Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.12996/gmj.2021.06Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorYıldırım, Malik Ejder
dc.contributor.authorBerk, Serdar
dc.contributor.authorKurtulgan, Hande Küçük
dc.contributor.authorTekin, Gülaçan
dc.contributor.authorTekin, Yusuf Kenan
dc.contributor.authorBaşer, Burak
dc.contributor.authorBağcı, Gökhan
dc.contributor.authorErşan, Serpil
dc.contributor.authorKılıçgün, Hasan
dc.date.accessioned2026-10-18T20:28:13.664170225Z
dc.date.available2026-10-18T20:28:13.664170225Z
dc.date.issued2020
dc.description.abstractObjective: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease characterized by obstructed airflow in the lungs. Pulmonary hypertension (PH) is a common complication of COPD and it is associated with pulmonary vascular remodelling. Monocyte chemoattractant protein-1 (MCP-1/CCL2) is one of the key chemokines associated with migration of monocytes and macrophages. Both MCP-1 and its receptor CCR2 have been declared to be involved in various diseases. We aimed to research a possible association of MCP-1 level, MCP-1 -2518 A/G and CCR2 190 A/G polymorphisms with COPD and pulmonary hypertension in this study. Material and methods: Eighty patients and eighty controls were included in the study. Serum MCP-1 levels were measured by ELISA method. Restriction fragment length polymorphism (RFLP) procedure was used to detect the genotypes of patients and control group. Results: MCP-1 levels were found to be significantly higher in COPD patients than in healthy controls (P=0.001) and patients with COPD + PH had higher serum MCP-1 levels than COPD patients (P=0.005). No association was found between MCP-1/CCR2 gene polymorphisms and patient groups (COPD and COPD + PH). Conclusion: MCP-1 level seems to be associated with both COPD and pulmonary hypertension. Increased MCP-1 expression may most likely to be involved in the pathogenesis of these diseases. © Copyright 2021 by Gazi University Medical Faculty
dc.description.sponsorshipOur study was approved by Sivas Cumhuriyet University Clinical Research Ethics Committee and supported by Sivas Cumhuriyet University Scientific Research Projects Unit (CUBAP). Eighty patients who applied to Sivas Cumhuriyet University Faculty of Medicine Department of Chest Diseases between 2017-2018 and eighty healthy controls were included in the study. To be younger than 18 years of age, another systemic disease, severe smoking, alcohol use, mental disability, malignancy and the presence of acute infection were exclusion criteria for the patients. The control group was chosen from individuals who did not have any systemic disease or mental disorder and who were not smoking and using alcohol.
dc.identifier.doi10.12996/gmj.2021.06
dc.identifier.endpage32
dc.identifier.issn2147-2092
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85098655614
dc.identifier.startpage28
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13388
dc.identifier.volume32
dc.identifier.wosWOS:000600546000006
dc.language.isoen
dc.publisherGazi Universitesi
dc.relation.ispartofGazi Medical Journal
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCCR2
dc.subjectCOPD
dc.subjectMCP-1
dc.subjectPolymorphism
dc.subjectPulmonary hypertension
dc.subjectchemokine receptor CCR2
dc.subjectmonocyte chemotactic protein 1
dc.subjectadult
dc.subjectallele
dc.subjectArticle
dc.subjectchronic obstructive lung disease
dc.subjectcontrolled study
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjectgene frequency
dc.subjectgenetic association
dc.subjectgenotype
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectprotein blood level
dc.subjectprotein expression
dc.subjectrestriction fragment length polymorphism
dc.titleThe association of MCP-1 level and MCP-1 -2518 A/G and CCR2 190 G/A gene polymorphisms with COPD and pulmonary hypertension; [MCP-1 düzeyi ve MCP-1 -2518 A/G ve CCR2 190 G/A Gen Polimorfizmlerinin KOAH ve Pulmoner Hipertansiyon ile İlişkisi]
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus1
rdl.citation.wos0
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.wos.indexEmerging Sources Citation Index (ESCI)